СОВРЕМЕННЫЕ ПОДХОДЫ К ТЕРАПИИ МУКОПОЛИСАХАРИДОЗОВ У ДЕТЕЙ
https://doi.org/10.15690/vsp.v13i3.1026
Аннотация
Об авторах
Н. В. Бучинская
Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Россия
И. А. Чикова
Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Россия
Е. А. Исупова
Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Россия
О. В. Калашникова
Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Россия
М. М. Костик
Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Россия
В. Г. Часнык
Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Россия
Список литературы
1. Tolar J., Grewal S. S., Bjoraker K. J., Whitley C. B., Shapiro E. G., Charnas L., Orchard P. J. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2008; 41: 531–535.
2. D’Aco K., Underhill L., Rangachari L., Arn P., Cox G. F., Giugliani R., Okuyama T., Wijburg F., Kaplan P. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur. J. Pediatr. 2012; 171: 911–919.
3. Platt F. M., Neises G. R., Reinkensmeier G., Townsend M. J., Perry V. H., Proia R. L., Winchester B., Dwek R. A., Butters T. D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997; 276: 428–431.
4. Jeyakumar M., Butters T. D., Cortina-Borja M., Hunnam V., Proia R. L., Perry V. H., Dwek R. A., Platt F. M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proceed. Nat. Acad. Sci. USA. 1999; 96: 6388–6393.
5. Andersson U., Smith D., Jeyakumar M., Butters T. D., Borja M. C., Dwek R. A., Platt F. M. Improved outcome of N-butyldeoxyga lactonojirimycin- mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol. Dis. 2004; 16: 506–515.
6. Cox T., Lachmann R., Hollak C., Aerts J., Van Weely S., Hrebi cek M., Platt F., Butters T., Dwek R., Moyses C., Gow I., Elstein D., Zimran A. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000; 355: 1481–1485.
7. Piotrowska E., Jakobkiewicz-Banecka J., Baranska S., TylkiSzymanska A., Czartoryska B., Wegrzyn A., Wegrzyn G. Genisteinmediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur. J. Hum. Genet. 2006; 14 (7): 846–852.
8. Kingma S. P., Wagemans T., Lilst L., Wijburq F. A., van Vlies N. Genistein increases glycosaminoglycan levels in mucopoly saccha ridosis type I cell models. J. Inherit. Metab. Dis. 2014; in press.
9. Kim K. H., Dodsworth C., Paras A., Burton B. K. High dose genistein aglycone therapy is safe in patients with mucopoly saccharidoses involving the central nervous system. Mol. Genet. Metab. 2013; 109 (4): 382–385.
10. Di Ferrante N., Nichols B. L., Knudson A. G., McCredie K. B., Singh J., Donnelly P. V. Mucopolysaccharide-storage diseases: corrective activity of normal human serum and lymphocyte extracts. Birth Defects. Orig. Article Ser. 1973; 9: 31–40.
11. Fratantoni J. C., Hall C. W., Neufeld E. F. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science. 1968; 162: 570–572.
12. Wiesmann U. N., Rossi E. E., Herschkowitz N. N. Treatment of metachromatic leukodystrophy in fibroblasts by enzyme replacement. New Engl. J. Med. 1971; 284: 672–673.
13. Kihara H., Porter M. T., Fluharty A. L. Enzyme replacement in cultured fibroblasts from metachromatic leukodystrophy. Birth Defects. Orig. Article Ser. 1973; 9: 19–26.
14. Church H., Tylee K., Cooper A., Thornley M., Mercer J., Wraith E., Carr T., O'Meara A., Wynn R. F. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 2007; 39: 207–210.
15. Souillet G., Guffon N., Maire I., Pujol M., Taylor P., Sevin F., Bleyzac N., Mulier C., Durin A., Kebaili K., Galambrun C., Bertrand Y., Froissart R., Dorche C., Gebuhrer L., Garin C., Berard J., Guibaud P. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003; 31: 1105–1117.
16. Vellodi A., Young E. P., Cooper A., Wraith J. E., Winchester B., Meaney C., Ramaswami U., Will A. bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch. Dis. Childhood. 1997; 76: 92–99.
17. Peters C., Shapiro E. G., Anderson J., Henslee-Downey P. J., Klemperer M. R., Cowan M. J., Saunders E. F., deAlarcon P. A., Twist C., Nachman J. B., Hale G. A., Harris R. E., Rozans M. K., Kurtzberg J., Grayson G. H., Williams T. E., Lenarsky C., Wagner J. E., Krivit W. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood. 1998; 91: 2601–2608.
18. Vellodi A., Young E., Cooper A., Lidchi V., Winchester B., Wraith J. E. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 1999; 22 (5): 638–648.
19. Valayannopoulos V., Wijburg F. A. Therapy for the mucopolysaccha ridoses. Rheumatology (Oxford). 2011; 50 (Suppl. 5): 49–59.
20. O’Brien J. S., Miller A. L., Loverde A. W., Veath M. L. Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts. Science. 1973; 181: 753–755.
21. Desnick R. J., Schuchman E. H. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev. Genomics Hum. Genet. 2012; 13: 307–335. Doi: 10.1146/annurev-genom-090711-163739.
22. Vera M., Le S., Kan S. H., Garban H., Naylor D., Mlikotic A., Kaitila I., Harmatz P., Chen A., Dickson P. Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients. Pediatr. Res. 2013; 74 (6): 712–720.
23. Ehlert K., Frosch M., Fehse N., Zander A., Roth J., Vormoor J. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr. Rheum. Online J. 2007; 5: 15.
24. Simonaro C., Frohberg M., Ge Y., Menq F., Schuchman E. A 63: treatment of arthritis in animal models of the mucopolysaccharidoses using a novel anti-inflammatory drug, pentosan polysulfate. Arthritis Rheum. 2014; 66 (Suppl. 11): 93.
25. Ortolano S., Vieitez I., Navarro C., Spuch C. Treatment of lysosomal storage diseases: recent patents and future strategies. Rec. Pat. Endocr. Metab. Immune Drug Discov. 2014; 8 (1): 9–25.
26. Baldo G., Giuqliani R., Matte U. Gene delivery strategies for the treatment of mucopolysaccharidoses. Exp. Opin. Deliv. 2014; 11 (3): 449–59.
27. Tardieu M., Zerah M., Husson B., de Bournonville S., Deiva K., Adamsbaum C., Vincent F., Hocquemiller M., Broissand C., Furlan V., Ballabio A., Fraldi A., Crystal R., Baugnon T., Roujeau T., Heard J. M., Danos O. Intracerebrae administration of AAVrh 10 carrying human SGSH and SUMF1 cDNAs in children with MPS IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 2014; in press.
28. Sanford M., Lo J. H. Esosulfase alfa: first global approval. Drugs. 2014; in press.
29. Kornfeld S. Lysosomal enzyme targeting. Biochem. Soc. Trans. 1990; 18 (3): 367–374.
30. Brands M. M., Hoogeveen-Westerveld M., Kroos M. A., Nobel W., Ruijter G. J., Ozkan L., Plug I., Grinberg D., Vilageliu L., Halley D. J., van der Ploeg Ans T., Reuser A. J. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet. J. Rare Dis. 2013; 8: 51.
31. Barbier A. J., Bielefeld B., Whiteman D. A., Natarajan M., Pano A., Amato D. A. The relationship between anti-idursulfatase antibody status and safety and efficacy outcomes in attenuated muco poly saccha ridosis II patients aged 5 years and older treated with intravenous idursulfase. Mol. Genet. Metab. 2013; 110 (3): 303–310.
32. Muenzer J. Overview of the mucopolysaccharidoses. Rheuma tology (Oxford). 2011; 50 (Suppl. 5): 4–12.
Рецензия
Для цитирования:
Бучинская Н.В., Чикова И.А., Исупова Е.А., Калашникова О.В., Костик М.М., Часнык В.Г. СОВРЕМЕННЫЕ ПОДХОДЫ К ТЕРАПИИ МУКОПОЛИСАХАРИДОЗОВ У ДЕТЕЙ. Вопросы современной педиатрии. 2014;13(3):35-43. https://doi.org/10.15690/vsp.v13i3.1026
For citation:
Buchinskaya N.V., Chikova I.А., Isupova E.А., Kalashnikova О.V., Kostik М.М., Chasnyk V.G. MODERN APPROACHES TO THERAPY FOR CHILDREN WITH MUCOPOLYSACCHARIDOSIS. Current Pediatrics. 2014;13(3):35-43. https://doi.org/10.15690/vsp.v13i3.1026
Просмотров: 726
Послать статью по эл. почте 
